The Canadian Arthritis Network hosts its Annual Conference 2000 in Toronto, bringing together researchers and clinicians to find solutions for the disease affecting over four million Canadians. The symposium will focus on new approaches to diagnosing and treating arthritis, including innovative strategies to repair cartilage defects.
The Prosorba® Column is a device that removes harmful antibodies and immune complexes from the blood of patients with rheumatoid arthritis. Patient trials are expected to evaluate its effectiveness and safety in treating this chronic inflammatory condition affecting over 250,000 Canadians.
The Canadian Arthritis Network hosted a conference showcasing advancements in arthritis research and one-stop services for industry and government. The event featured key developments in therapeutics, diagnostics, and devices.
Researchers found that delaying treatment by nine months results in significant permanent damage and reduced disease progression. Early therapy with a second-line agent like Hydroxychloroquine reduces the need for more expensive treatments, including surgery.